CRVS Corvus Pharmaceuticals

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2024 financial results.

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on for instant telephone access to the event. The live webcast may be accessed via the section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit .

INVESTOR CONTACT:

Leiv Lea

Chief Financial Officer

Corvus Pharmaceuticals, Inc.



MEDIA CONTACT:

Sheryl Seapy

Real Chemistry





EN
31/07/2024

Underlying

CRVSCorvus Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Corvus Pharmaceuticals

 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial...

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announc...

September 10, 2024 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual G...

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company’s prese...

September 3, 2024 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Provides Business Update and Reports Second Qua...

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma (PTCL) Advancing Toward Initial Enrollment in Q3 2024; New Complete Response Achieved in Ongoing Phase 1/1b Clinical Trial Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Aug. 06, 2024 (GLOBE NE...

August 6, 2024 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelit...

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), ...

August 1, 2024 1 EN
 PRESS RELEASE
Free
CRVS Corvus Pharmace...

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2...

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-fre...

July 31, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch